TCF7L2 rs7901695: What Your Genotype Means
The rs7901695 variant is a single-nucleotide polymorphism located within an intron of the TCF7L2 gene on chromosome 10. In human genome-wide association studies, it is strongly associated with an increased predisposition to developing type 2 diabetes. However, rs7901695 primarily acts as a tag SNP in strong linkage disequilibrium with rs7903146, the main regulatory driver variant at this genetic locus.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| TT | Carriers of the TT genotype possess two copies of the common protective or non-risk allele. Individuals with this genotype generally exhibit baseline population risk for type 2 diabetes attributable to this locus. It is associated with standard beta-cell insulin secretion and normal incretin pathway function. | Favorable |
| CT | Heterozygous CT carriers possess one copy of the risk-associated C allele and one copy of the non-risk T allele. This genotype is associated with a modestly elevated statistical predisposition to developing type 2 diabetes. The heightened risk can be significantly mitigated through routine physical activity and standard metabolic lifestyle choices. | Informational |
| CC | Homozygous CC individuals have inherited two copies of the risk-associated allele at this tag SNP. In population studies, this genotype correlates with reduced pancreatic beta-cell sensitivity and higher relative odds of developing type 2 diabetes compared to TT carriers. Regular screening of glycemic markers such as fasting glucose or HbA1c may be prudent. | Higher attention |
Genetic Location and Nature of rs7901695
The single-nucleotide polymorphism rs7901695 represents an exchange between cytosine (C) and thymine (T) alleles situated within the non-coding intronic territory of the transcription factor 7-like 2 (TCF7L2) gene on chromosome 10q25.2. Because it is positioned in an intron, it does not alter the amino acid sequence of the final protein. Rather, genetic mapping indicates that rs7901695 serves primarily as a proxy or 'tag' SNP. In most human ancestry groups, it is in high linkage disequilibrium (LD) with rs7903146, another nearby variant that functional genomic studies identify as the chief causal regulatory variant influencing local chromatin accessibility and gene expression.
The Biological Role of the TCF7L2 Gene
TCF7L2 encodes a high-mobility group (HMG) box transcription factor that operates downstream of the Wnt/beta-catenin signaling cascade. This pathway plays a fundamental role in embryonic development, cellular differentiation, and systemic glucose homeostasis. Within human metabolic tissues—most notably pancreatic beta-cells and the enteroendocrine cells of the gastrointestinal tract—TCF7L2 regulates proinsulin processing, insulin secretion in response to glucose, and the incretin axis involving hormones such as glucagon-like peptide-1 (GLP-1). Perturbations in TCF7L2 expression impair pancreatic beta-cell survival and compromise the body's normal compensatory insulin response.
Strength of Scientific Evidence and Disease Risk
The association between genetic variants in TCF7L2 and type 2 diabetes susceptibility represents one of the most consistently replicated findings in human complex genetics. Large-scale genome-wide association studies across diverse international cohorts demonstrate that carriers of the risk-associated alleles exhibit roughly a 1.3- to 1.5-fold increased relative risk of type 2 diabetes per risk allele. Carriers of the risk allele C at rs7901695 (co-inherited with the T risk allele of rs7903146) generally display reduced early-phase insulin secretion, higher fasting proinsulin levels, and lower glucose tolerance. While statistical evidence is exceptionally strong across Europeans and South Asians, effect sizes can vary in cohorts with differing linkage disequilibrium structures, such as certain East Asian or Indigenous populations.
Translating Genetic Predisposition to Daily Health
Carrying risk alleles at rs7901695 reflects a statistical predisposition to impaired insulin secretion, not a clinical diagnosis of diabetes. Monogenic forms of diabetes follow strict inheritance patterns, but type 2 diabetes is polygenic and deeply sensitive to environmental factors. Clinical trials such as the Diabetes Prevention Program have established that lifestyle interventions—including a nutrient-dense diet, routine aerobic exercise, weight management, and stress reduction—can substantially attenuate or offset the heightened genetic risk imparted by TCF7L2 variants. Individuals interested in their metabolic risk should monitor standard clinical markers, such as fasting plasma glucose and HbA1c, under the supervision of a healthcare provider.
How common is this variant?
The risk allele (C) frequency is approximately 0.30 in populations of European ancestry and about 0.35 in individuals of South Asian descent according to gnomAD data. Frequencies can vary across other global groups due to differing linkage disequilibrium and ancestral genetic diversity.
Frequently asked questions
Does having the C allele at rs7901695 guarantee I will develop diabetes?
No. The presence of the risk-associated C allele only confers an increased statistical predisposition, not a clinical diagnosis. Many individuals who carry one or two risk alleles never develop type 2 diabetes, particularly when they maintain a healthy weight and engage in regular exercise.
What is the difference between rs7901695 and rs7903146?
Both variants are located within the TCF7L2 gene, but functional studies indicate that rs7903146 is the primary causal regulatory variant driving differences in gene activity. rs7901695 acts as a tag SNP that is co-inherited with rs7903146 due to high linkage disequilibrium in most populations.
Can lifestyle changes overcome the genetic risk associated with TCF7L2?
Yes. Large-scale clinical trials have demonstrated that lifestyle modifications, including a balanced diet and regular physical activity, can significantly reduce the incidence of type 2 diabetes even among individuals carrying high-risk TCF7L2 genotypes.
Does this genetic variant affect how someone responds to diabetes medications?
Some observational studies suggest TCF7L2 variants may modestly influence beta-cell responsiveness to certain oral therapies, such as sulfonylureas. However, patients should never alter or adjust prescription medications without consulting their physician or pharmacist.
Sources & further reading
Educational information only, last refreshed 9/10/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs7901695?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29